Develops experimental immune-modulating medicines for autoimmune diseases and cancer, including treatments designed to restore immune balance or activate the body’s tumor-fighting response.
10-K for FY2025, filed Mar 13, 2026Nektar Therapeutics (Nektar, we) is a clinical stage, research-based drug discovery biopharmaceutical company focused on discovering and…View ↗
By modulating the immune system, our drug candidates target pathways that play critical roles in a wide range of serious diseases. In…View ↗
In oncology, we focus on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response…View ↗
We believe it is important to maintain a diverse pipeline of new drug candidates to build on the value of our business. Our discovery…View ↗
Nektar receives royalties tied to partner drug sales, though it has sold rights to receive royalties on several products; it may also receive upfront license payments and payments tied to research, clinical progress, regulatory progress or sales. Its former product sales were paid after shipment.
10-K for FY2025, filed Mar 13, 2026Generally, for our collaboration arrangements that include sales-based royalties, we have granted our collaboration partner a license to…View ↗
License, collaboration and other revenueView ↗
Our revenue has been derived from our collaboration agreements with partners, under which we may receive a combination of revenue elements…View ↗
We invoiced and recognized product sales when title and risk of loss passed to the customer, which generally occurred upon shipment.…View ↗
10-K for FY2025, filed Mar 13, 2026
FY2025 revenue by product or service ↗$55.2M
10-K for FY2025, filed Mar 13, 2026
$55.2M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product sales
Sold outright
|
0.0%
FY2022: 22%
|
Product sales, FY2025
$0 Sources
|
Sold outright |
|
Non-cash royalty revenue related to the sales of future royalties
Usage-based
10-K for FY2025, filed Mar 13, 2026 |
99%
FY2022: 76%
|
Non-cash royalty revenue related to the sales of future royalties, FY2025
$54.9M Sources
|
Usage-based |
|
License, collaboration and other revenue
|
0.5%
FY2022: 2.1%
|
License, collaboration and other revenue, FY2025
$300K Sources
|
Nektar's revenue comes mainly from pharmaceutical and biotechnology companies through collaboration arrangements. Partners may pay for licenses, research work, clinical or regulatory milestones, and royalties tied to sales of approved drugs.
10-K for FY2025, filed Mar 13, 2026
10-K for FY2025, filed Mar 13, 2026
Our revenue has been derived primarily from customers in the pharmaceutical and biotechnology industries. Revenue from Baxalta (a…View ↗
No. It lost $164.1M in FY2025.
8-K, filed Sep 25, 2026
In August 2023, Nektar Therapeutics (the “Company”) filed a complaint in the U.S. District Court for the Northern District of California…View ↗
Shrinking. Revenue fell 46% in 4 years, from $101.9M in FY2021 to $55.2M in FY2025, about 14% a year.
Pipeline focus
The older report describes Lilly conducting clinical work on rezpegaldesleukin; the latest report says Nektar has regained full rights and describes its own development of the candidate, alongside preclinical tumor-necrosis-factor receptor candidates.
10-K for FY2022, filed Feb 28, 2023 10-K for FY2025, filed Mar 13, 2026
Research platform
The older report describes an advanced polymer-conjugate technology platform and manufacturing PEGylation reagents; the latest report focuses on discovering and developing drug candidates and says the facility was sold.
10-K for FY2022, filed Feb 28, 2023 10-K for FY2025, filed Mar 13, 2026Our advanced and proven polymer conjugate technology platform is focused on conjugating polyethylene glycol to a pharmaceutically active…View ↗
Competes with Regeneron, Leo Pharma, Eli Lilly and, Galderma, Symbiotix, Apogee Therapeutics, Janssen Pharmaceuticals, AstraZeneca, Tizona Therapeutics, Sangamo Therapeutics, Quell Therapeutics, Sonoma Biotherapeutics, GentiBio, Kyvema Therapeutics, Tract Therapeutics, Sanofi SA, ImmunityBio, Nkarta, NKMax America, and Roche/Genentech
10-K for FY2025, filed Mar 13, 2026There are a number of competitors in various stages of clinical development that are working on programs which are designed to correct the…View ↗
Loading...